Sonnet BioTherapeutics Holdings, Inc. (SONN)

NASDAQ: SONN · IEX Real-Time Price · USD
1.57
-0.07 (-4.51%)
Oct 6, 2022 10:10 AM EDT - Market open

Company Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action.

The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.

Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy.

It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6.

Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings logo
Country United States
Industry Biotechnology
Sector Health Care
Employees 9
CEO Michael Pruitt

Contact Details

Address:
100 Overlook Center
Princeton, New Jersey 08540
United States
Phone 609-375-2227
Website sonnetbio.com

Stock Details

Ticker Symbol SONN
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency US Dollars
CIK Code 1106838
CUSIP Number 15930P206
ISIN Number US83548R1059
SIC Code 5812

Key Executives

Name Position
Dr. Pankaj Mohan Ph.D. Founder, Chairman. Chief Executive Officer and Pres
Dr. John K. Cini Ph.D. Chief Scientific Officer and Co-Founder
Jay Cross Chief Financial Officer
Susan Dexter Chief Technical Officer
Dr. Richard T. Kenney FACP, M.D. Chief Medical Officer
Manuel Dafonseca Head of Clinical Operations

Latest SEC Filings

Date Type Title
Oct 4, 2022 8-K Current Report
Sep 29, 2022 8-K Current Report
Sep 21, 2022 8-K Current Report
Sep 19, 2022 424B4 Prospectus
Sep 19, 2022 8-K Current Report
Sep 16, 2022 EFFECT Notice of Effectiveness
Sep 16, 2022 8-K Current Report
Aug 31, 2022 S-3 Registration statement under Securities Act of 1933
Aug 25, 2022 8-K Current Report
Aug 25, 2022 DEF 14A Other definitive proxy statements